Current dilemmas in hepatitis virus C management. What should we do after achieving sustained virologic response?

Conthe, Andrés; Ahumada, Adriana; Gallego Durán, Rocío; Marti-Aguado, David; Ibáñez-Samaniego, Luis.
Gastroenterol. hepatol. (Ed. impr.) ; 46(10): 826-829, dic. 2023. ilus
Artículo en Inglés | IBECS (España) | ID: ibc-228235

Documentos relacionados

  1. Current dilemmas in hepatitis virus C management. What should we do after achieving sustained virologic response?
  2. Efficacy of direct-acting anti-viral therapy on chronic, naïve hepatitis C virus patients of Punjab, Pakistan: a cross-sectional study.
  3. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
  4. Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
  5. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
  6. [A real-world study of sofosbuvir-based drug treatment for hepatitis C virus genotype 6 infection in Hainan region of China].
  7. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.
  8. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.
  9. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
  10. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort.